Skip to main content Skip to navigation
Purified NA/LE Mouse Anti-Human PD-L1 (CD274)
Product Details
Down Arrow Up Arrow


BD Pharmingen™
B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1; hPD-L1
Human (QC Testing)
Mouse BALB/c IgG2b, κ
Human PD-L1
Flow cytometry, Functional assay (Tested During Development)
1.0 mg/ml
No azide/low endotoxin: Aqueous buffered solution containing no preservative, sterile filtered(0.2µm pore size membrane). Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
RUO


Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Recommended Assay Procedures

The 29E.2A3 monoclonal antibody can reportedly bind to Alexa Fluor™ 700 antibody conjugates during multicolor immunofluorescence staining experiments. This interaction may be circumvented by sequentially staining with the 29E.2A3 antibody first, followed by a wash step, and then further staining with an Alexa Fluor™ 700 antibody conjugate of interest.

BD® CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.  However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  3. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
568081 Rev. 1
Antibody Details
Down Arrow Up Arrow
29E.2A3

The 29E.2A3 monoclonal antibody specifically recognizes Programmed cell death 1 ligand 1 (PDCD1 ligand 1, PDCD1L1, PDCD1LG1) which is also known as Programmed death ligand 1 (PD-L1 or PDL1) as well as CD274, or B7 homolog 1 (B7-H1, B7H1). PD-L1 (CD274) and PD-L2 (CD273) are type I transmembrane glycoproteins that belong to the B7 family within the Ig gene superfamily and serve as ligands for CD279 (Program Death 1/PD-1). PD-L1 (CD274) is expressed on antigen-presenting cells including activated monocytes, macrophages, and dendritic cells (DCs) as well as activated T cells, B cells, NK cells, and keratinocytes. PD-L1 (CD274) is also variably expressed on placental trophoblasts, myocardial endothelium, cortical thymic epithelial cells, and tumor cells. PD-L1-mediated signaling through PD-1 regulates T cell responses important for providing protective immunity while maintaining peripheral tolerance. This immune signaling checkpoint may also suppress antitumor immune responses and prevent tumor rejection. The 29E.2A3 antibody reportedly blocks PD-L1 (CD274) binding to CD279 (PD-1) and can enhance the proliferation and cytokine production of activated T cells.

        

568081 Rev. 1
Format Details
Down Arrow Up Arrow
NA/LE
NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.
NA/LE
568081 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligand on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003; 170:1257-1266. (Clone-specific: Flow cytometry, Functional assay, Immunohistochemistry). View Reference
  2. Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.. Nature. 2017; 549(7670):101-105. (Clone-specific: Flow cytometry). View Reference
  3. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006; 30:802-810. (Clone-specific: Immunohistochemistry). View Reference
  4. Hughes MJ, McGettrick HM, Sapey E. Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore. J Immunol Methods. 2020; 483:112795. (Clone-specific: Flow cytometry). View Reference
  5. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-268. (Immunogen: ELISA, Flow cytometry). View Reference
  6. Llinas L, Lazaro A, de Salort J, Matesanz-Isabel J, Sintes J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett. 2011; 134(2):113-121. (Clone-specific: Flow cytometry). View Reference
  7. Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis.. Eur J Immunol. 2003; 33(11):3117-26. (Clone-specific: Flow cytometry, Functional assay). View Reference
View All (7) View Less
568081 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.